VYGR - Voyager Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
18.03
-0.26 (-1.42%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close18.29
Open18.24
Bid18.70 x 800
Ask24.00 x 800
Day's Range17.32 - 18.34
52 Week Range8.10 - 31.91
Volume350,074
Avg. Volume485,788
Market Cap582.748M
Beta3.05
PE Ratio (TTM)N/A
EPS (TTM)-2.61
Earnings DateMay 7, 2018 - May 11, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.73
Trade prices are not sourced from all markets
  • GlobeNewswire51 minutes ago

    Voyager Therapeutics Receives FDA Guidance on Development Path for VY-AADC for Parkinson’s Disease and Provides Clinical Update

    Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today announced feedback from a Type C meeting with the U.S. Food and Drug Administration (FDA).  Based on the written response from the FDA, Voyager continues to plan to submit for review a biologics license application (BLA) for VY-AADC based on the nonclinical and clinical safety and efficacy data from the pivotal program, including plans to submit a BLA based on data from the randomized, placebo-controlled Phase 2 trial alone, or if needed, from the randomized, placebo-controlled Phase 3 trial. In addition, Voyager today announced positive interim results from a Phase 1 posterior trajectory trial that achieved enhanced coverage of the putamen, reduced surgical times, and improvements in patients’ motor function at six months that were consistent with improvements achieved from patients in Cohorts 2 and 3 at the same time point in Voyager’s Phase 1b trial with VY-AADC.

  • ACCESSWIRE15 days ago

    Initiating Free Research Reports on ZIOPHARM Oncology and Three Other Biotech Equities

    Stock Research Monitor: VYGR, VTVT, and ZSAN LONDON, UK / ACCESSWIRE / July 2, 2018 / If you want a free Stock Review on ZIOP sign up now at www.wallstequities.com/registration . WallStEquities.com recalls ...

  • GlobeNewswire19 days ago

    Voyager Therapeutics Appoints Andre Turenne as President and Chief Executive Officer

    Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today announced the appointment of G. Andre Turenne as president and chief executive officer of Voyager effective July 16, 2018, at which time he will also become a member of the Voyager Board of Directors. Mr. Turenne joins Voyager with extensive strategic business development and commercial leadership experience, including nearly 12 years at Genzyme and Sanofi where he most recently served as Sanofi’s senior vice president, global head, business development and licensing responsible for partnering activities across all of Sanofi’s business units.

  • Benzinga26 days ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Casi Pharmaceuticals Inc (NASDAQ: CASI ) stock was ...

  • GlobeNewswire26 days ago

    Voyager Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted for VY-AADC for the Treatment of Parkinson’s Disease

    Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation for Voyager’s VY-AADC gene therapy treatment for Parkinson’s disease in patients with motor fluctuations that are refractory to medical management. “The RMAT designation was based on our Phase 1b clinical data with VY-AADC and represents an important milestone for the program and recognition of this gene therapy as a potential treatment for Parkinson’s disease,” said Robert Pietrusko, Pharm.D., senior vice president of regulatory affairs and quality assurance at Voyager.

  • ACCESSWIRE2 months ago

    Complimentary Technical Snapshots on VIVUS and Three More Biotech Stocks

    Under evaluation this morning are these four equities: VIVUS Inc. (NASDAQ: VVUS), Voyager Therapeutics Inc. (NASDAQ: VYGR), vTv Therapeutics Inc. (NASDAQ: VTVT), and Zosano Pharma Corp. (NASDAQ: ZSAN). Shares in Campbell, California headquartered VIVUS Inc. plummeted 14.00%, ending Tuesday's trading session at $0.79.

  • GlobeNewswire2 months ago

    Voyager Therapeutics Announces Management Change

    Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today announced that Jane Henderson, Voyager’s chief financial officer and senior vice president of corporate development, has advised the Company of her intent to pursue other career opportunities that are closer to home and plans to leave the company June 8, 2018. Allison Dorval, vice president of finance, will assume the roles of principal financial officer and principal accounting officer. “On behalf of the Board and our leadership team here at Voyager, I would like to thank Jane for her role in strengthening our financial operations, improving our capital structure, and helping to drive our ongoing business development activities including our recent successful collaboration with AbbVie,” said Steve Paul, M.D., president and chief executive officer of Voyager.

  • GlobeNewswire2 months ago

    Voyager Therapeutics Announces Additional Data at the American Society of Gene and Cell Therapy 2018 Annual Meeting

    Voyager’ s gene therapy vector for Friedreich’ s ataxia prevents central and peripheral disease progression in preclinical model out to one year after a single administration. Durable safety data generated ...

  • Benzinga2 months ago

    Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 17) Abaxis Inc (NASDAQ: ABAX ) (rallying for second straight session ...

  • GlobeNewswire2 months ago

    Voyager Therapeutics Announces New Data at the American Society of Gene and Cell Therapy 2018 Annual Meeting

    Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today announced new data presentations at the American Society of Gene and Cell Therapy (ASGCT) taking place May 16-19, 2018, in Chicago, Ill. Voyager presented results for VY-SOD101, which targets the superoxide dismutase 1 gene (SOD1), the first mutant gene discovered to be causal for the development of amyotrophic lateral sclerosis (ALS). The results demonstrated that a one-time administration of VY-SOD101 lowered SOD1 mRNA levels by 78% in the spinal cord motor neurons of non-human primates.

  • GlobeNewswire2 months ago

    MRI Interventions Announces Strategic Agreement with Voyager Therapeutics for Neurosurgical Device Service, Supply and Development

    MRI Interventions, Inc. (MRIC) today announced a strategic agreement with Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases.

  • Benzinga2 months ago

    The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

    The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) saw a modest uptick this week amid a slew of biotech earnings news flow and a deal announced in the space. Here's a compilation of key biotech ...

  • Associated Press2 months ago

    Voyager Therapeutics: 1Q Earnings Snapshot

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 63 cents. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...

  • GlobeNewswire2 months ago

    Voyager Therapeutics Announces First Quarter 2018 Financial Results and Corporate Highlights

    CAMBRIDGE, Mass., May 10, 2018-- Voyager Therapeutics, Inc., a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today reported its first ...

  • GlobeNewswire3 months ago

    Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy 2018 Annual Meeting

    Five oral presentations and 10 poster presentations focus on Voyager’ s clinical and preclinical programs, novel capsid optimization efforts and manufacturing capabilities. Investor and analyst breakfast ...

  • GlobeNewswire3 months ago

    Report: Exploring Fundamental Drivers Behind W.R. Grace, NCI Building, Robert Half International, CACI International, PROS, and Voyager Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, April 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • Analysts’ Recommendations for AbbVie in April 2018
    Market Realist3 months ago

    Analysts’ Recommendations for AbbVie in April 2018

    In April 2018, the FDA notified AbbVie (ABBV) and Neurocrine Biosciences that it would need more time to review liver function test data provided by AbbVie with its new drug application for Elagolix for the management of endometriosis-associated pain, extending its Prescription Drug User Fee Act goal date by three months to 3Q18. In 4Q17, the FDA granted Elagolix priority review. In clinical trials, Elagolix was evaluated for safety and efficacy in ~1,700 women with moderate-to-severe endometriosis-related pain.

  • Exploring Voyager Therapeutics’ Cash Flows and Valuation Metrics
    Market Realist3 months ago

    Exploring Voyager Therapeutics’ Cash Flows and Valuation Metrics

    Voyager Therapeutics (VYGR) spent $61.3 million on operating activities in 2017 compared to $42.4 million in 2016. In comparison, it generated $47.3 million from investing activities in 2016. The company’s positive investing cash flow in 2016 was attributable to proceeds from the maturities of marketable securities of $165.1 million, and it was partially offset by securities purchases of $112.4 million.

  • Insight into the Financial Performance of Voyager Therapeutics
    Market Realist3 months ago

    Insight into the Financial Performance of Voyager Therapeutics

    In the future, Voyager is expected to earn collaboration revenues from Sanofi and AbbVie. This increase of $20 million was primarily attributable to a jump in external research costs and employee expenses. Its external research costs rose from $20.4 million in 2016 to $33.8 million in 2017.

  • Analysts Rate Voyager Therapeutics and Its Peers in April
    Market Realist3 months ago

    Analysts Rate Voyager Therapeutics and Its Peers in April

    Voyager Therapeutics (VYGR) is a clinical-stage gene therapy company with a focus on developing treatments for severe neurological diseases. It focuses on those neurological diseases for which an adeno-associated virus (or AAV) gene therapy can reduce the symptoms experienced by patients. Of the 13 analysts covering Voyager Therapeutics in April 2018, five have given the stock “strong buy” ratings, five have given it “buy” ratings, and three have given it “hold” ratings.

  • Exploring Voyager Therapeutics’ Research Pipeline
    Market Realist3 months ago

    Exploring Voyager Therapeutics’ Research Pipeline

    Voyager Therapeutics’ (VYGR) research pipeline consists of six programs targeting different neurological indications, including advanced Parkinson’s disease, amyotrophic lateral sclerosis (or ALS), Huntington’s disease, and Alzheimer’s disease. Voyager Therapeutics’ most advanced clinical candidate is VY-AADC for the treatment of advanced Parkinson’s disease.

  • TheStreet.com4 months ago

    4 Strong Buy Biotech Stocks Poised to Explode

    Here comes the growth. These four strong buy biotech stocks are potentially on the cusp of very big growth.

  • Associated Press4 months ago

    Voyager Therapeutics reports 4Q loss

    The Cambridge, Massachusetts-based company said it had a loss of 40 cents per share. The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research ...

  • Should You Buy Voyager Therapeutics (VYGR) Ahead of Earnings?
    Zacks4 months ago

    Should You Buy Voyager Therapeutics (VYGR) Ahead of Earnings?

    Voyager Therapeutics (VYGR) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.